Aspect Biosystems Presents New Preclinical Data on Adrenal Bioprinted Tissue Therapeutics at ENDO 2025
Preclinical data highlight the potential of Aspect's adrenal Bioprinted Tissue Therapeutics to restore adrenal function and treat primary adrenal insufficiency
Article content
VANCOUVER, British Columbia — Aspect Biosystems, a biotechnology company pioneering the development of Bioprinted Tissue Therapeutics (BTTs) as a new category in regenerative medicine, today announced new preclinical data at ENDO 2025, the Endocrine Society's annual meeting held in San Francisco. The company presented an oral and poster presentation highlighting that Aspect's adrenal BTTs can restore adrenal function, following natural daily hormone rhythms and maintaining long-term performance in animal models of primary adrenal insufficiency.
Article content
Primary adrenal insufficiency is a serious, life-threatening condition in which the adrenal glands fail to produce sufficient levels of essential hormones such as cortisol, a key regulator of the body's stress response. The current standard of care involves daily hormone replacement therapy, which does not fully replicate the body's natural circadian hormone rhythms and is associated with significant drug-related side effects. This can leave patients with a poor quality of life and at risk of ongoing health challenges, including potentially fatal adrenal crises.
Aspect's adrenal BTTs were developed using the company's proprietary full-stack tissue therapeutic platform, which combines AI-powered bioprinting, computational design tools, therapeutic cells, and advanced biomaterials.
Article content
In preclinical studies, adrenal BTTs containing human adrenal cells were implanted into adrenalectomized mice. These BTTs produced cortisol in response to adrenocorticotropic hormone (ACTH) stimulation—which is normally secreted from the brain—and followed the animals' natural circadian fluctuations in hormone levels. When exposed to high levels of injected ACTH, these mice demonstrated rapid increases in circulating cortisol, confirming that the adrenal BTTs were functionally responsive. In contrast, control animals receiving cell-free implants showed no significant cortisol levels and did not respond to ACTH stimulation. Importantly, adrenal BTTs remained functional in vivo throughout the study period of over six months and improved animal survival.
Article content
'Our research shows that Aspect's adrenal BTTs successfully replicate healthy human adrenal gland function by releasing cortisol in a pattern that follows the natural daily rhythms of hormone release and by responding appropriately to a stimulus that mimics a stress response,' said Sam Wadsworth, PhD, Chief Scientific Officer at Aspect Biosystems. 'These results demonstrate that our off-the-shelf, implantable cell therapy can work in harmony with the body's physiology and has real potential to serve as a functional cure for primary adrenal insufficiency.'
Article content
'At Aspect, we're making breakthrough progress with our Bioprinted Tissue Therapeutics platform to restore complex biological functions across a range of serious endocrine and metabolic diseases,' said Tamer Mohamed, Chief Executive Officer of Aspect Biosystems. 'This latest advance in primary adrenal insufficiency, a rare and life-threatening condition with limited treatment options, showcases the potential of a bioengineered cell therapy to recreate natural hormone function and deliver a truly disease-modifying solution. This reflects our mission to develop regenerative medicines capable of achieving functional cures for patients with serious and underserved diseases.'
Article content
About ENDO
Article content
Hosted by the Endocrine Society, ENDO is the leading global meeting on endocrinology research and clinical care. The Endocrine Society is the world's oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions. Learn more at www.endocrine.org/.
Article content
About Aspect Biosystems
Article content
Aspect Biosystems is a biotechnology company pioneering the development of Bioprinted Tissue Therapeutics (BTTs) to transform how we treat some of the most elusive diseases. Aspect's BTTs are designed to replace, repair, or supplement biological function inside the body. Aspect is creating these next-generation cell therapies by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, computational design tools, therapeutic cells, and advanced biomaterials. Aspect is advancing a pipeline of BTTs across multiple disease areas in the endocrine and metabolic space including diabetes, obesity, rare endocrine disorders, and liver disease. Aspect's pipeline development strategy involves both proprietary programs as well as strategic partnerships, including a collaboration with Novo Nordisk focused on diabetes and obesity. For more information, please visit www.aspectbiosystems.com and follow on LinkedIn.
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
2 hours ago
- CBC
New asbestos handling standards coming for Manitoba workers
Social Sharing New regulations to protect workers from asbestos exposure will come into effect in Manitoba this fall, and officials with the Manitoba Federation of Labour say they can't come soon enough, as workers continue to die from exposure. "Asbestos is the number one occupational killer in Canada and in Manitoba," federation president Kevin Rebeck said Monday, adding that approximately six people die every year in the province from asbestos exposure. According to the province, the regulations — which are expected to come into effect in October — will require workers to be trained and certified through an intensive training program prior to having any contact with asbestos. "So having an intensive training program that keeps workers safe, lets them know what the proper equipment is, and allows them to do those jobs minimizing their risk is vitally important," Rebeck said. Asbestos was commonly used in roofing materials, insulation and other building products for decades in Canada. It was not fully banned in Canada until 2018, although its use was largely phased out by around 1990. During demolition and construction projects, microscopic fibres of asbestos can be released and trapped in people's lungs. It's known to cause several health conditions, including cancer. Rebeck said the new regulations are important because many people who work with the substance don't have a true understanding of how dangerous it is and how to avoid being exposed. "For too many young workers, newcomers who might be hired to these low-wage jobs and exposed to this deadly substance without the protections that they need, this law will make a huge difference," he said. Mark McKean, the owner of Manitoba business Breathe Easy Eco Solutions, which offers asbestos and mould remediation services in the province, said the new regulations will follow a model for asbestos exposure prevention that has been in place in B.C. since 2024, and was the first of its kind in the country. "It's a more stringent course, it goes over risk assessments and conditions of asbestos, and what to do." McKean said. McKean said he has been hoping for years that Manitoba would start to "tighten up" its asbestos regulations, which he said he believes will now happen when the new regulations go into place this fall. He added he believes many of the most serious asbestos exposure cases in Manitoba likely happened years or even decades ago, but says the new regulations are important so that work happening now does not lead to exposure, and possible illness or death. In a Monday email, a spokesperson for Manitoba Labour Minister Malaya Marcelino explained the province's rationale behind the new regulations. "Everyone deserves to come home safe from work, especially when dealing with hazardous materials like asbestos," the statement reads in part. "That's why our government is moving forward with new regulations this year to better protect Manitoba workers. These changes will include mandatory safety certification for anyone handling asbestos, ensuring stronger safeguards are in place where they matter most."
CBC
3 hours ago
- CBC
Canadian obesity rate doubled during pandemic: study
New research published in Canadian Medical Association Journal found that the obesity rate doubled during the COVID-19 pandemic, something researchers say could be linked to more sedentary behaviour and mental health issues driven by isolation.
CBC
3 hours ago
- CBC
Measles cases in Alberta surpass all of U.S.
After 30 confirmed measles cases were reported over the weekend, Alberta's case count now surpasses that of the entire U.S. With summer events happening across the province, health officials are concerned the outbreak is set to get worse.
